Pazopanib in patients with primary multi-metastatic bone Ewing sarcoma
Pazopanib was well-tolerated in young patients, even when it was administered with chemotherapy and radiation therapy together. Pazopanib turned out to be effective in patients with primary multi-metastatic Ewing sarcoma and particularly could be considered as an option for them. This regimen deserves further investigation.
Authors
- Radosław Chaber (ORCID: https://orcid.org/0000-0002-6862-9142)
- Renata Tomaszewska (ORCID: https://orcid.org/0000-0003-2801-9216)
- Borys Przybyszewski
- Tomasz Koziński (ORCID: https://orcid.org/0000-0003-2321-8590)
- Jadwiga Węcławek‐Tompol (ORCID: https://orcid.org/0000-0001-8972-9516)
- Dorota Sęga-Pondel
- Katarzyna Bilska (ORCID: https://orcid.org/0000-0001-5556-8021)
- Anna Raciborska
- Justyna Antoniuk-Majchrzak
- Anna Zelwiańska
Institutions
- Medical University of Silesia (PL)
- Wroclaw Medical University (PL)
- Mother and Child Foundation (GB)
- Silesian Center for Heart Disease (PL)
- University of Rzeszów (PL)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.3389/fonc.2025.1653015
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00